The findings indicate that the sensitivities to EGFR inhibitors (afatinib, erlotinib, and gefitinib) and MAPK inhibitors (doramapimod) were significantly greater in the high-MLRS group (Figure 6F), indicating the potential importance of these agents in inhibiting the progression of malignant tumors. This evidence concerns the gene EGFR and cancer.